This Literature case, reported by a Health Care Professional, concerns a 60 Years old Female patient of unreported 
ethnicity.   History Lung a arcinoma metastatic. Initially, she received vinorvelbine (25 mg/m2) and 
cispiatin (75 mg/n2) as 1st line chemotherapy treatment. However, tumor progression was noted later and 
0 elbine/cisplafiri was a by gefitinib as the 2nd line therapy treatment, further disease o 0? ession was 
later observed her epidermal growth factor receptor (EFGR) with an observed mutation (L858R point 
r. o . in exon 21). Concomitant Medications: full vitamin supplementation and dexamethasone. After 
observation of the EGFR, she pemetrexed (unknown manufacturer) 500 mg/m2, every 21 days with full 
vitamins 00 ion and dexamethasone for treatment of grade IV lung adenocarcinoma with spine 
metastasis. No specific complaints were documented after the 1st cycle with the exception of mild nausea, 
vomiting and 000 appetite. However, after the patient completed the 2nd cycle of pemetrexed 500 mg/m2 on 06-
Jun-2011, she complained of lower leg weakness, general myalgia at the night after pemetrexed was administered. 
Print Time: 02-SEP-2014 01:09 PM If a field is blank, there is no data for that field Page 268 of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
She denied taking any statin derivates or Chinese herbal medication. On day 3 after pemetrexed administration, 
she went to the emergency department due to progressive extremity weakness and inability to walk. Respiratory 
distress Cleve o . The laboratory data showed abruptly increased serum concentrations of creatine kinase (CK) 
(17571 WI), aspartate aminotransferase (567 U/L) and blood urea nitrogenkreatine were 32.8/0.66 mg/dL. She 
was d ed with severe rhabdomyolysis. Emergent intubation was performed because of respiratory failure and 
the she was to the intensive care unit on the same day. She was carefully treated and the concentration of 
CK o ally returned to normal. However, poor weaning process and extubation attempt failed. Therefore, she 
was transferred to the respiratory care unit for long term care. Finally, she was successfully weaned on the 7th of 
July 2011 and was capable of walking on the August 2011. Events with Outcome: respiratory failure (Recovered), 
0 0I0 is (Recovered). The status of the pemetrexed was not directly reported. The a related the 
pemetrexed to the fhabdomyolysis; the other events were not directly assessed. Literature Citation: Huang M.-
&Tsai J.-R.Shen M.-C,Chou S.-H.Yang C.-J. Pemetrexed as a possible cause of severe rhabdomyolysis in the 
treatment of lung cancer. Lung Cancer. 2012; 76(3) 491-492.